Production & Sales

Arcutis introduces roflumilast cream for paediatric atopic dermatitis

Arcutis Biotherapeutics has launched Zoryve (roflumilast) cream at a concentration of 0.05% for the treatment of mild to moderate atopic dermatitis in children aged between two and five years in the US.

Samsung Bioepis to acquire commercial rights for Byooviz in Europe

Samsung Bioepis is set take over the European commercialisation of Byooviz (ranibizumab) from January 2026 under an asset purchase agreement (APA) with Biogen.

Hovione finalises $100m investment for East Windsor site expansion in US

Hovione has concluded an initial $100m investment cycle for expanding its manufacturing site in East Windsor, New Jersey, as part of its strategy to extend operations in the US and broaden drug substance and product capabilities.

Citius Oncology finalises McKesson deal for Lymphir distribution

Citius Oncology has entered into an agreement with McKesson for the distribution of Lymphir (denileukin diftitox-cxdl).

Polpharma Biologics signs biosimilars licensing deals with MS Pharma

Polpharma Biologics has entered into licensing agreements with MS Pharma to commercialise three proposed biosimilars in the Middle East and North Africa (MENA) region.

Johnson & Johnson, Pacira partner to expand osteoarthritis treatment options

Johnson & Johnson MedTech has entered into a strategic co-promotion agreement with Pacira BioSciences, aimed at enhancing the treatment options available for osteoarthritis of the knee.

Sagent, Qilu partner to commercialise complex injectable products in US

Sagent Pharmaceuticals and Qilu Pharmaceutical have announced a strategic collaboration to commercialise a portfolio of complex injectable products for the US market.

Lakeside Holding agrees to acquires Hupan Pharmaceutical

Lakeside Holding (Lakeside), through its subsidiary Sichuan Hupan Jincheng Enterprise Management, has entered into an equity transfer agreement for the acquisition of Hupan Pharmaceutical.

Samsung Biologics signs $1.24bn manufacturing deal with Asian pharma company

Samsung Biologics, a leading contract development and manufacturing organization (CDMO), has secured a contract manufacturing deal valued at $1.24bn with an Asia-based pharmaceutical company.